Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Verrica Pharmaceuticals Inc.

VRCA · Nasdaq · CIK 0001660334 · Healthcare · Biotechnology

INSIDER SIGNAL

65.2 / 100

4 buyers · 6 purchase transaction lines · $210.9K gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+28.0 / 35
Purchase size+10.6 / 25
Role+13.0 / 20
Recency+3.6 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: CEO and President (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS4
PURCHASE CONCENTRATION60%Largest buyer: Rieger Jayson · $125.7K
CLUSTER BUYING · 15D4 insidersPeak activity: 2026-08-14–2026-08-18

Roles in the peak window: CEO and President, CMO, Chief Operating Officer, Interim CFO. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Rosenberg Noah L.CMO
●●
Rieger JaysonCEO and President
●●
Kirby John J.Interim CFO
●
Zawitz DavidChief Operating Officer
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

65.2 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 65.6
  2. 65.4
  3. 65.3
  4. 65.2
  5. 65.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

12Purchases
0Sales
1Other Form 4 lines
10SEC filings · 365 days
BUYING6 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-17.0%
3M
-30.6%
6M
-19.6%
12M
-7.0%

Volatility & liquidity

Volatility
103.1%
Beta
—
Avg daily value
USD 262,414

Valuation

Market cap
USD 70.6M
P/E
—

Fundamentals

Profit margin
-50.3%
ROE
-72.3%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
196,221
Previous report
202,755
Avg daily volume
48,284
Days to cover
4.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-18Rosenberg Noah L.Purchase (P)Common Stock2,030USD 4.92USD 9,988SEC filing ↗
2026-08-18Kirby John J.Purchase (P)Common Stock5,000USD 4.93USD 24,650SEC filing ↗
2026-08-17Zawitz DavidPurchase (P)Common Stock6,000USD 4.98USD 29,880SEC filing ↗
2026-08-17Rosenberg Noah L.Purchase (P)Common Stock4,200USD 4.91USD 20,622SEC filing ↗
2026-08-17Rieger JaysonPurchase (P)Common Stock5,000USD 4.91USD 24,550SEC filing ↗
2026-08-14Rieger JaysonPurchase (P)Common Stock20,000USD 5.06USD 101,200SEC filing ↗
2025-11-25Zawitz DavidPurchase (P)Common Stock10,000USD 4.24USD 42,400SEC filing ↗
2025-11-25Rosenberg Noah L.Purchase (P)Common Stock2,357USD 4.24USD 9,994SEC filing ↗
2025-11-25Rieger JaysonPurchase (P)Common Stock94,311USD 4.24USD 399,879SEC filing ↗
2025-11-25Manning Paul BPurchase (P)Common Stock4,126,142USD 4.24USD 17,494,842SEC filing ↗
2025-11-25Kirby John J.Purchase (P)Common Stock3,536USD 4.24USD 14,993SEC filing ↗
2024-11-22Stalfort John A IIIPurchase (P)Common Stock1,123,595USD —USD —SEC filing ↗
2024-11-22Rieger JaysonPurchase (P)Common Stock280,898USD —USD —SEC filing ↗
2024-11-22Manning Paul BPurchase (P)Common Stock22,921,348USD —USD —SEC filing ↗
2023-12-29EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock115,774USD 7.24USD 838,204SEC filing ↗

Form 4 evidence

13 transaction lines in the latest 365-day window; 112 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-18Rosenberg Noah L.Purchase (P)Common Stock2,030USD 4.92USD 9,988SEC filing ↗
2026-08-18Kirby John J.Purchase (P)Common Stock5,000USD 4.93USD 24,650SEC filing ↗
2026-08-17Zawitz DavidPurchase (P)Common Stock6,000USD 4.98USD 29,880SEC filing ↗
Show recent Form 4 evidence (12 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-18Rosenberg Noah L.Purchase (P)Common Stock2,030USD 4.92USD 9,988SEC filing ↗
2026-08-18Kirby John J.Purchase (P)Common Stock5,000USD 4.93USD 24,650SEC filing ↗
2026-08-17Zawitz DavidPurchase (P)Common Stock6,000USD 4.98USD 29,880SEC filing ↗
2026-08-17Rosenberg Noah L.Purchase (P)Common Stock4,200USD 4.91USD 20,622SEC filing ↗
2026-08-17Rieger JaysonPurchase (P)Common Stock5,000USD 4.91USD 24,550SEC filing ↗
2026-08-14Rieger JaysonPurchase (P)Common Stock20,000USD 5.06USD 101,200SEC filing ↗
2025-12-23Kirby John J.Award / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗
2025-11-25Zawitz DavidPurchase (P)Common Stock10,000USD 4.24USD 42,400SEC filing ↗
2025-11-25Rosenberg Noah L.Purchase (P)Common Stock2,357USD 4.24USD 9,994SEC filing ↗
2025-11-25Rieger JaysonPurchase (P)Common Stock94,311USD 4.24USD 399,879SEC filing ↗
2025-11-25Manning Paul BPurchase (P)Common Stock4,126,142USD 4.24USD 17,494,842SEC filing ↗
2025-11-25Kirby John J.Purchase (P)Common Stock3,536USD 4.24USD 14,993SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerVRCA
CIK0001660334
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history112 transaction lines from 2020-08-13 to 2026-08-18
51 P purchase lines · 33 S sale lines · 28 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.